Phase I/II radioimmunotherapy with high-dose 90Y-labeled humanized MN-14 [labetuzumab Y-90] alone or combined with doxorubicin and peripheral blood stem cell rescue (PBSCR) in medullary thyroid cancer (MTC) grant application title: Radioimmunotherapy of MTC with Y-90 humanized MN14 anti-CEA Mab and doxorubicin

Trial Profile

Phase I/II radioimmunotherapy with high-dose 90Y-labeled humanized MN-14 [labetuzumab Y-90] alone or combined with doxorubicin and peripheral blood stem cell rescue (PBSCR) in medullary thyroid cancer (MTC) grant application title: Radioimmunotherapy of MTC with Y-90 humanized MN14 anti-CEA Mab and doxorubicin

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2011

At a glance

  • Drugs Labetuzumab Y-90 (Primary) ; Doxorubicin
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Feb 2009 Additional trial centre Garden State Cancer Center and Center for Molecular Medicine and Immunology reported by ClinicalTrials.gov, last updated 28 Feb 2009.
    • 03 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top